Fairvalue-Calculator Fairvalue-Calculator
EN DE

Corporativo Fragua, S.A. (CGSBF) Fair Value & Analysis

Healthcare · US · Market cap $2.8B

Price$29.66
Fair Value$40.13
Upside+35.3%
Quality88/100
Evidence: Medium Range $22.35 – $66.88

Analysis

Corporativo Fragua, S.A. (CGSBF) currently trades at $29.66, while our model-based Fair Value estimate is $40.13 — implying the stock looks roughly 35.3% undervalued today. We read business quality at 88/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Corporativo Fragua, S.A.B. de C.V., together with its subsidiaries, operates pharmacy stores in Mexico. The company purchases and sells medicine products, perfumes, photography equipment, household goods, food, miscellaneous items, and others. It is also involved in the provision of maintenance and surveillance services, and medical services; operation service of distribution centers; management, logistics, and personnel services; maintenance and repair of furniture; transport and distribution of goods; purchase, sale, and rental of buildings; and manufacture and packaging of non-alcoholic beverages. The company was founded in 1942 and is based in Guadalajara, Mexico.

Open the full interactive analysis →

Similar stocks

JD Health International Inc (JDHIF) +376% Alibaba Health Information Technology Limited (ALBBY) -20% Raia Drogasil S.A (RADL3) -8% Yifeng Pharmacy Chain Co (603939) +106% Clicks Group (CLCGY) +45% Sugi Holdings (SGIPF) +98%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.